Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
Original Article: Eleven Biotherapeutics completes Vicinium manufacturing for ongoing clinical trials in non-muscle invasive bladder cancer
NEXT ARTICLE